晚期非小细胞肺癌免疫治疗前结肠生理性18F-FDG摄取与疗效及肠道菌群相关
高结肠SUVmax组无应答者比例更高(p=0.033),无进展生存期更短(4.1 vs 11.3个月,HR 1.94,95%CI 1.11-3.41,p=0.005)。23例患者的宏基因组测序显示低盲肠SUVmax组菌群多样性更高(p=0.046)。
要点
- ICI治疗前结肠生理性18F-FDG摄取高与更差疗效相关
- 高结肠SUVmax组无进展生存期显著缩短(4.1 vs 11.3个月)
- 低盲肠SUVmax组肠道菌群多样性更高,富集双歧杆菌科等
核心结论
- ICI启动前PET/CT结肠生理性18F-FDG摄取较低与晚期NSCLC患者更好的临床结局和更高的肠道菌群多样性相关。
- 结肠生理性18F-FDG摄取可能作为肠道菌群组成的潜在新型标志物并预测该人群临床结局。
研究设计与样本
- 对每个结肠段进行盲法勾画,按平均结肠SUVmax中位数及每个结肠段SUVmax分为低组与高组。
- 比较低SUVmax组与高SUVmax组的缓解率、无进展生存期(PFS)和总生存期(OS)。
- 对23例患者采用宏基因组测序分析肠道菌群组成。
主要发现
- 高结肠SUVmax组无应答者比例更高(p=0.033)。
- 高结肠SUVmax组PFS显著更短(4.1 vs 11.3个月,HR 1.94,95%CI 1.11-3.41,p=0.005)。
- 高盲肠SUVmax与数值上更短的OS相关(10.8 vs 27.6个月,HR 1.85,95%CI 0.97-3.53,p=0.058)。
- 宏基因组测序显示各组间菌群组成存在差异。
- 低盲肠SUVmax组菌群多样性更高(p=0.046),且富集双歧杆菌科、毛螺菌科和拟杆菌科。
临床怎么用
- 对于拟接受ICI治疗的晚期NSCLC患者,治疗前PET/CT所测结肠生理性18F-FDG摄取或可辅助预测疗效与预后。
- 结肠SUVmax较高提示可能疗效不佳,可考虑结合肠道菌群评估优化治疗决策。
局限性
- 肠道菌群分析仅纳入23例患者,样本量有限。
- 盲肠SUVmax与OS的关联仅达到边缘统计学意义(p=0.058)。
- 研究为单中心回顾性设计,结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICI) represent the backbone treatment for advanced non-small cell lung cancer (NSCLC). Emerging data suggest that increased gut microbiome diversity is associated with favorable response to ICI and that antibiotic-induced dysbiosis is associated with deleterious outcomes. 18F-FDG physiologic colonic uptake on PET/CT increases following treatment with antibiotics (ATB) and could act as a surrogate marker for microbiome composition and predict prognosis. The aim of this study was to determine if 18F-FDG physiologic colonic uptake prior to ICI initiation correlates with gut microbiome profiling and clinical outcomes in patients with advanced NSCLC. METHODS: Seventy-one patients with advanced NSCLC who underwent a PET/CT prior to ICI were identified. Blinded colonic contouring was performed for each colon segment and patients were stratified according to the median of the average colon SUVmax as well as for each segment in low vs. high SUVmax groups. Response rate, progression-free survival (PFS), and overall survival (OS) were compared in the low vs. high SUVmax groups. Gut microbiome composition was analyzed for 23 patients using metagenomics sequencing. RESULTS: The high colon SUVmax group had a higher proportion of non-responders (p = 0.033) and significantly shorter PFS (4.1 vs. 11.3 months, HR 1.94, 95% CI 1.11-3.41, p = 0.005). High caecum SUVmax correlated with numerically shorter OS (10.8 vs. 27.6 months, HR 1.85, 95% CI 0.97-3.53, p = 0.058). Metagenomics sequencing revealed distinctive microbiome populations in each group. Patients with low caecum SUVmax had higher microbiome diversity (p = 0.046) and were enriched with Bifidobacteriaceae, Lachnospiraceae, and Bacteroidaceae. CONCLUSIONS: Lower colon physiologic 18F-FDG uptake on PET/CT prior to ICI initiation was associated with better clinical outcomes and higher gut microbiome diversity in patients with advanced NSCLC. Here, we propose that 18F-FDG physiologic colonic uptake on PET/CT could serve as a potential novel marker of gut microbiome composition and may predict clinical outcomes in this population.
引用
- Cvetkovic L, Régis C, Richard C, et al. Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2020. PMID: 33128571. doi:10.1007/s00259-020-05081-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。